
Get What You're Owed From Your Health Insurance Plan
By Kimberly Lankford
From Kiplinger's Personal Finance
Depending on your health insurance policy, you may have noticed that you need to get permission from your insurer before it will pay for a medication, treatment or procedure your doctor prescribes—even if it's covered by your plan. This extra step, called prior authorization, is becoming more common with most types of health insurance, including Medicare Advantage, employer coverage, and individual plans sold through HealthCare.gov or your state health insurance marketplace. When your health plan requires prior authorization, your doctor must provide evidence that the specific care is medically necessary and is the best course of action in your situation.
Prior-authorization requirements have increased significantly over the past few years. For example, virtually all enrollees in Medicare Advantage plans are required to obtain prior authorization for some services, and these insurers made nearly 50 million prior-authorization determinations in 2023, up from 37 million in 2021, according to health policy research organization KFF.
Insurers don't always approve these requests. In 2023, for example, Medicare Advantage insurers fully or partially denied 3.2 million prior-authorization requests, according to KFF. Insurers say that prior authorization provides a vital screen to ensure patients receive safe, evidence-based care and to reduce low-value and inappropriate services so that coverage is as affordable as possible.
The American Medical Association, however, calls prior authorization 'an overused process that interferes with patients receiving timely care, or even any care at all.' More than one in four physicians report that delays or denials related to prior authorization have led to a serious adverse event, such as hospitalization, disability or even death for a patient in their care.
And prior authorization isn't the only obstacle you may encounter. You may face a denial of your claim after you receive a procedure or treatment if the insurer decides that your coverage doesn't include it or you didn't get the necessary prior authorization first.
Related Stories
5/1/2025
1/13/2025
But you don't have to take no for an answer, and perseverance often pays off. Less than 12 percent of Medicare Advantage prior-authorization denials were appealed in 2023, but more than 81 percent of the appealed denials were partially or fully overturned, KFF found. Only 1 percent of in-network denials were appealed for policies sold on HealthCare.gov, but 44 percent of the denials were overturned at the first level of appeal, KFF found. You may also be able to successfully appeal denials from employer health insurance plans or traditional Medicare—whether for prior authorization or for a service you already received—although few people know their appeal rights.
'Never accept the first denial letter you get, because it is often just the default reaction to treatment protocols, especially if it's something new,' says Suzanne Garner, 47, of San Diego, who was first diagnosed with breast cancer seven years ago. 'It doesn't matter if the treatment is fully FDA-approved and, in the case of oncology care, even if the National Cancer Coalition and ASCO [the American Society of Clinical Oncology] have endorsed it to be a piece of standard of care,' she says. 'If it's new, for a while, it's likely to be denied.'
By appealing, Garner has successfully reversed more than 20 prior-authorization denials and five denials for claims after receiving a bill. 'At the beginning, I was very intimidated when I would get these denials and big cost estimates, and I remember crying and saying to my husband that we would have to go into our daughter's college fund or our retirement fund,' Garner says. 'For the most part, we figured it out, but it took being brave, advocating for myself and waiting on hold a lot. Don't be afraid to appeal, and don't be afraid to ask a lot of questions.'
Here's what you need to know to appeal a health insurance denial, whether it involves a prior authorization request or a big bill following a procedure or treatment that you believe your insurance should cover.
Help From Your Doctor
The procedure for appealing a denial varies depending on the type of health insurance. 'You have to follow the timeline and the instructions on the explanation of benefits or the Medicare summary notice,' says Tatiana Fassieux, education and training specialist for California Health Advocates.
Whatever the appeals process, you should contact your doctor's office right away after you receive a denial. 'There's a certain amount of time to appeal—sometimes it's 30 to 60 days, depending on your insurance plan. But we might not be alerted to that denial until 21 days have passed, and sometimes it's a fight against time,' says Michelle Vanderwaall, who spent more than 20 years as an operations manager for several surgical specialties in a San Diego hospital system.
Your medical team may regularly deal with appeals, developing expertise in navigating them. The staff at the office of Garner's oncologist were instrumental in overturning denials for PET scans, breast MRIs, an oophorectomy (ovary removal surgery) and other procedures. Several of the denials were reversed after her oncologist got on the phone with a doctor at the insurance company and explained her specific needs, a step called a peer-to-peer review.
Bruce A. Brod, a physician and clinical professor of dermatology at the University of Pennsylvania Perelman School of Medicine, says that he sometimes can get a denial reversed through a peer-to-peer review. But the conversation isn't necessarily with other dermatologists, so he may need to take extra time to explain the patient's needs.
Other Sources of Assistance
Some doctor's offices are more helpful with appeals than others, and you may need to advocate for yourself. But that can be difficult to do when you're learning new medical terminology while dealing with a major diagnosis.
Garner learned a lot from other cancer survivors in support groups, and she shares the knowledge she has collected, too. For example, she helped a neighbor who was diagnosed with breast cancer get 14 months of coverage for an infusion her oncologist recommended. The insurance company wanted to pay for only eight months. Garner used Outcomes4Me, a cancer-support app that aggregates medical research for patients based on their specific diagnosis (Garner now works for Outcomes4Me), and they looked through PubMed (a resource of medical literature from the National Institutes of Health) and Google Scholar to find newer studies. 'We were able to pull together a compelling case with numerous studies that showed it was more effective to have the full 14 months,' she says.
You may get help from a nurse navigator or a social worker at the hospital or your doctor's office. Additionally, nonprofits and advocacy groups specializing in your disease may provide resources and help with claims. You may also get help from organizations such as Triage Cancer (
'I think one of the major challenges is that there is an overarching lack of awareness about the appeals process,' says Monica Bryant, a cancer-rights attorney and chief operating officer for Triage Cancer.
Bryant has helped reverse denials in a variety of situations. She helps gather the evidence to build the patient's case, which can include medical records, test results, literature, clinical trial results, a personal narrative or a letter from the doctor.
©2025 The Kiplinger Washington Editors, Inc. Distributed by Tribune Content Agency, LLC.
The views and opinions expressed are those of the authors. They are meant for general informational purposes only and should not be construed or interpreted as a recommendation or solicitation. The Epoch Times does not provide investment, tax, legal, financial planning, estate planning, or any other personal finance advice. The Epoch Times holds no liability for the accuracy or timeliness of the information provided.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Is UnitedHealth a Buy for Long-Term Investors?
UnitedHealth is going through a rough patch, underscored by decelerating earnings, management changes, and some bad publicity. Over the last month, its stock price has collapsed and now hovers around a five-year low. Recent commentary from management coupled with a flurry of insider buys suggest the business is still positioned well for the long run. 10 stocks we like better than UnitedHealth Group › With shares down by more than 40%, UnitedHealth Group (NYSE: UNH) is the poorest-performing stock in the Dow Jones Industrial Average so far this year. Over the last month or so, there has been no shortage of storylines surrounding America's largest health insurers. And if the share price movements are any indication, most of the news isn't great. Let's dig into what has driven UnitedHealth stock off a cliff, and explore whether or not it remains a good buy for long-term investors. A significant influence on a stock price, at least over the short term, is how a company's quarterly earnings are perceived. Generally speaking, if a company beats Wall Street estimates or raises its outlook, shares rise. On the other hand, if investors aren't impressed by the company's performance, they may choose to sell the stock. During UnitedHealth's fourth-quarter and full-year 2024 earnings call in January, management issued earnings guidance of $28.15 to $28.65 per share. Things took an unexpected turn when it reported first-quarter earnings on April 17. Management is now guiding in the range of $24.65 to $25.15 for earnings per share (EPS). Two primary factors contributed to the downward revision. First, utilization rates from the company's Medicare Advantage businesses were higher than management was forecasting. These dynamics increase near-term costs, thereby stifling profitability. Second, the company's Optum Health division -- which serves as a pharmacy benefits manager -- has been struggling on reimbursement due to a combination of cuts to Medicare as well as changes in insurance plans in certain market demographics. Unfortunately for investors, UnitedHealth's drama didn't stop at the operational hiccups detailed above. About a month after the first-quarter earnings report, the company announced that CEO Andrew Witty had resigned. If this weren't enough to get investors hitting the panic button, The Wall Street Journal followed up that news with a report that UnitedHealth was under investigation from the Department of Justice (DOJ) regarding fraudulent activity in Medicare billing. Management was quick to deny these claims and called the report "deeply irresponsible." As of this writing (June 3), shares are trading around $300, near a five-year low. The graph above shows that UnitedHealth is valued right in between insurance giants Humana and Cigna on a forward price-to-earnings (P/E) basis. Just a month ago, the company's forward P/E was roughly twice as high as now and trading for a premium compared to the competition. Given the extreme valuation compression over the last several weeks, I am inclined to think much (if not all) of the bad news is priced into the stock already. A downward revision in guidance and changes in management are the main talking points surrounding UnitedHealth at the moment. But in the company's first-quarter earnings release and the the announcement of Witty's resignation, management added that the company should return to growth by next year. The company's new CEO, Stephen Hemsley, purchased $25 million in UnitedHealth stock following the sell-off last month. This was met with another $6.6 million of insider buys from other executives. I think this signals confidence in the company's long-term prospects. In my view, these insider buys suggest management believes that UnitedHealth is poised to return to growth. While the near-term price action might continue exhibiting some volatility, I think the shares remain a solid opportunity for long-term investors. Given the valuation trends explored in this article, I think now is an opportunity to buy the dip in UnitedHealth Group stock at a bargain valuation. Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Adam Spatacco has no position in any of the stocks mentioned. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy. Is UnitedHealth a Buy for Long-Term Investors? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
Why Universal Health Services (UHS) Shares Are Trading Lower Today
Shares of hospital management company Universal Health Services (NYSE:UHS) fell 5.7% in the afternoon session after Chief Financial Officer Steve Filton noted during a recent conference that procedural volumes (an important driver of hospital revenue) "have been slower to recover back to historical levels than we might have imagined." Filton also voiced concern over the Trump administration's proposed federal spending bill, particularly its implications for healthcare funding. Since UHS derives a significant portion of its revenue from government programs like Medicare and Medicaid, the anticipated cuts to Medicaid could significantly affect the company, especially in regions with high dependency on public healthcare funding. The shares closed the day at $177.76, down 6.2% from previous close. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Universal Health Services? Access our full analysis report here, it's free. Universal Health Services's shares are not very volatile and have only had 8 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. The previous big move we wrote about was 28 days ago when the stock gained 5.9% after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides agreed to pause some tariffs for 90 days, signaling a potential turning point in ongoing tensions. This rollback cuts U.S. tariffs on Chinese goods to 30% and Chinese tariffs on U.S. imports to 10%, giving companies breathing room to reset inventories and supply chains. However, President Trump clarified that tariffs could go "substantially higher" if a full deal with China wasn't reached during the 90-day pause, but not all the way back to the previous levels. Still, the agreement has cooled fears of a prolonged trade war, helping stabilize expectations for global growth and trade flows and fueling renewed optimism. The optimism appeared concentrated in key trade-sensitive sectors, particularly technology, retail, and industrials, as lower tariffs reduce cost pressures and restore cross-border demand. Universal Health Services is down 1.1% since the beginning of the year, and at $177.77 per share, it is trading 26.4% below its 52-week high of $241.52 from September 2024. Investors who bought $1,000 worth of Universal Health Services's shares 5 years ago would now be looking at an investment worth $1,628. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 hours ago
- Yahoo
New Research Underscores the Important Role of Value-Based Care (VBC) in Improving Primary Care Access for Traditional Medicare Patients
Study also sheds light on how agilon health's VBC model can enable primary care physicians to provide high-quality care for all seniors, including those with Traditional Medicare WESTERVILLE, Ohio, June 09, 2025--(BUSINESS WIRE)--agilon health (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced new research demonstrating the promising role of value-based care (VBC) in maintaining primary care for senior patients when supported by agilon health, a VBC-enablement company. The study was published in the May 2025 issue of Health Affairs Scholar. "Primary care is foundational for Medicare beneficiaries, especially those with chronic conditions. Despite its importance, many senior patients, particularly ones with Traditional Medicare (TM), have difficulties finding a primary care provider (PCP) and establishing this enormously critical longitudinal relationship," said Karthik Rao, MD, chief medical officer, agilon health. "As PCPs play a key role in providing comprehensive care to patients, we wanted to examine the role of VBC in improving primary care access in this population." Using claims data, researchers compared two groups of PCPs with TM patients in their panels: one group that received support from agilon health to adopt a VBC model and one group that maintained prevailing payment structures, primarily fee-for-service (FFS). Unlike FFS models that reward volume, VBC incentivizes PCPs to spend more time with patients and focus on their quality of care. The following results were observed in the study: After shifting to VBC, PCPs saw eight more new TM patients per year compared to the matched cohort of physicians who did not transition to the full-risk model, representing an approximate 35% relative increase in new TM patient volume, a statistically significant finding (P < 0.001). PCPs shifting to VBC kept their practices open to new TM patients for 0.7 more months per year on average – nearly one full month annually – compared to the other group (P < 0.001), a statistically meaningful increase in availability in the context of shrinking access and PCP workforce shortages nationally. "This study provides timely, independent validation of agilon health's VBC approach, confirming its role in increasing availability of primary care access for Medicare patients, including TM patients who historically face more limited options," added Dr. Rao. "While agilon's model is built around supporting physicians in full-risk arrangements through Medicare Advantage (MA) and ACO REACH contracts, this study shows that our model can have an even greater impact on communities by helping PCPs improve access to care across all of their Medicare patients." Study design Using FFS claims data from 2019 to 2023, researchers compared two groups of PCPs with at least 50 TM patients in their panels: 208 PCPs who received support to adopt a VBC model for TM and MA patients in 2022 ("adopters"), and 3,657 similar PCPs who maintained their existing payment models (FFS) ("nonadopters"). Researchers evaluated changes in two key outcomes between the two groups each year before, during and after VBC adoption. These outcomes included the number of new TM patients seen annually and the number of months each year that physician panels remained open to new TM patients. Researchers used difference-in-differences statistical methods to isolate the effect of joining the VBC model while accounting for other time-based trends. The primary study limitation was the nonexperimental design with a self-selected group of VBC-adopting PCPs. National trends in primary care and the promising role of VBC Access to primary care remains insufficient, despite its critical role in the U.S. healthcare system. Many areas are at risk of becoming "primary care deserts," and even well-resourced health systems have started restricting the acceptance of new patients, regardless of insurance type. Additionally, a national shortage of PCPs is projected to reach 57,000 by 2040. Compounding the issue, Medicare payments have dropped by 29% since 2001 after adjusting for physician practice costs. In response, some PCPs have been limiting new patient intake for TM beneficiaries. VBC models offer a promising path forward, leading to high-quality, cost-effective care. The Center for Medicare & Medicaid Innovation (CMMI) recently announced its goal to increase the share of Medicare beneficiaries in two-sided risk models. Unlike traditional FFS models, full-risk VBC arrangements provide PCPs with fixed payments based on patient demographics and complexity. In exchange, PCPs are held accountable for total medical spending and quality of care. These arrangements incentivize PCPs to proactively manage healthcare needs through efficient team-based approaches. By supporting care delivery transformation, it may also expand PCPs' capacity to serve more patients while maintaining high-quality care. About agilon health agilon health is the trusted partner empowering physicians to transform health care in our communities. Through our partnerships and purpose-built platform, agilon is accelerating at scale how physician groups and health systems transition to a value-based Total Care Model for their senior patients. agilon provides the technology, people, capital, process, and access to a peer network of 2,200+ primary care physicians that allow its physician partners to maintain their independence and focus on the total health of their most vulnerable patients. Together, agilon and its physician partners are creating the healthcare system we need – one built on the value of care, not the volume of fees. The result: healthier communities and empowered doctors. agilon is the trusted partner in 30 diverse communities and is here to help more of our nation's leading physician groups and health systems have a sustained, thriving future. For more information, visit and connect with us on LinkedIn. View source version on Contacts Investor Contacts Evan Smith, CFASVP, Investor Leland Thomasinvestors@ Media Contacts Stephanie LawSenior Director, Marketing & Maureen MerkleCorporate Communicationsmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data